Assertio Holdings, Inc. (NASDAQ:ASRT)

Depomed, Inc. (Depomed), incorporated on August 7, 1995, is a specialty pharmaceutical company initially focused on neurology, pain and other diseases of the central nervous system. In January 2011, the United States Food and Drug Administration (FDA) approved Gralise (gabapentin) once-daily tablets for the management of postherpetic neuralgia. The Company is developing and commercializing a number of pharmaceutical products for neurology, pain and other central nervous system conditions and diseases. The Company’s products include Gralise, Glumetza, Serada and DM-1992. Gralise (gabapentin) is its once-daily formulation of gabapentin for the management of postherpetic neuralgia (PHN). Glumetza is the Company's once-daily treatment for adults with type 2 diabetes that is commercialized in the United States by Santarus, Inc. (Santarus). In March 2011, the Company completed enrollment in Breeze 3. In June 2012, the Company acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc.